Digestive Disease Interventions 2021; 05(01): 050-054
DOI: 10.1055/s-0040-1722267
Review Article

Intratumoral and Oncoviral Immunotherapy

Rahul A. Sheth
1   Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
› Institutsangaben


Immunotherapy is a paradigm-shifting advance in cancer care, but despite their success, contemporary immunotherapy strategies are limited by several factors. The objective response rates to checkpoint inhibitor therapy remain below 50%, and the toxicities associated with systemically administered immunotherapies, particularly combination immunotherapy regimens, can be devastating. Intratumoral immunotherapies represent a burgeoning paradigm in immuno-oncology designed to address these limitations. The direct delivery of intratumoral immunotherapies can result in concentrations of the therapeutic agent at levels that would likely be far too toxic if administered systemically. In this review, I summarize the sound biological framework underlying intratumoral immunotherapies as well as provide an overview of the major categories of intratumoral agents currently under investigation. I also emphasize the components of this treatment strategy that are relevant for image-guided interventionalists based on existing clinical experience.


Eingereicht: 01. Juli 2020

Angenommen: 25. November 2020

19. Januar 2021 (online)

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA